{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:14:48Z","timestamp":1789391688714,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Introduction\/objective<\/jats:title>\n<jats:p>Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This post-hoc analysis evaluated the effect of temporary discontinuation and reinitiation of tofacitinib on disease control in patients with RA in the vaccine sub-study of the long-term extension (LTE) study ORAL Sequel (NCT00413699).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The sub-study of ORAL Sequel was a randomized, parallel-group, open-label study. Patients who received tofacitinib 10\u00a0mg twice daily for \u2265\u20093\u00a0months in ORAL Sequel were randomized to receive continuous (tofacitinib monotherapy\/with methotrexate) or interrupted (tofacitinib withdrawn for 2 weeks post-randomization then reinitiated as monotherapy\/with methotrexate) treatment. Efficacy assessments included ACR20\/50\/70 response rates, change from baseline (\u2206) in C-reactive protein (CRP), Health Assessment Questionnaire-Disability Index (HAQ-DI), Disease Activity Score in 28 joints, erythrocyte sedimentation rate (DAS28-4 [ESR]), Clinical Disease Activity Index (CDAI), Patient Global Assessment of arthritis (PtGA), Pain (Visual Analog Scale [VAS]), and Physician Global Assessment of arthritis (PGA). Safety was assessed throughout.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The sub-study included 99 patients each in the continuous and interrupted treatment groups. ACR20\/50 response rates, \u2206CRP, \u2206HAQ-DI (day 15), \u2206DAS28-4 (ESR), \u2206CDAI, \u2206PtGA, \u2206Pain (VAS), and \u2206PGA were significantly worse in interrupted vs continuous patients during dose interruption, but were generally similar to pre-interruption\/continuous treatment levels 28 days post-reinitiation. A numerically higher proportion of interrupted patients reported adverse events (49.5%) vs continuous patients (35.4%).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Tofacitinib efficacy can be re-established after temporary withdrawal and reinitiation. The safety profile of patients who temporarily discontinued tofacitinib in the sub-study was consistent with previous tofacitinib LTE studies over 9\u00a0years.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Clinical trial registration number<\/jats:title>\n<jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00413699\">NCT00413699<\/jats:ext-link><jats:table-wrap><jats:table><jats:tbody>\n<jats:tr>\n<jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold>\u2022 <jats:italic>In this sub-study of the long-term extension (LTE) study, ORAL Sequel, the efficacy of tofacitinib was re-established after temporary withdrawal (2\u00a0weeks) and reinitation of treatment in patients with RA.<\/jats:italic>\u2022 <jats:italic>Patients with RA who temporarily discontinued tofacitinib had similar safety events to those reported in previous LTE studies.<\/jats:italic>\u2022 <jats:italic>The results of this sub-study were consistent with a post-hoc analysis of pooled data from two LTE studies, ORAL Sequel and A3921041, which assessed the efficacy of tofacitinib following a treatment discontinuation period of 14\u201330\u00a0days.<\/jats:italic><\/jats:td>\n<\/jats:tr>\n<\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s10067-020-04956-1","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T03:03:55Z","timestamp":1581476635000},"page":"2127-2137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis"],"prefix":"10.1007","volume":"39","author":[{"given":"Jeffrey","family":"Kaine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Tesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Takiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"DeMasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisy","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshika","family":"Soma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vara","family":"Bandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wollenhaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,12]]},"reference":[{"key":"4956_CR1","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","volume":"73","author":"M Cross","year":"2014","unstructured":"Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, Williams B, Gabriel S, Lassere M, Johns N, Buchbinder R, Woolf A, March L (2014) The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73:1316\u20131322. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204627","journal-title":"Ann Rheum Dis"},{"key":"4956_CR2","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","volume":"376","author":"DL Scott","year":"2010","unstructured":"Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376:1094\u20131108. https:\/\/doi.org\/10.1016\/S0140-6736(10)60826-4","journal-title":"Lancet"},{"key":"4956_CR3","first-page":"S32","volume":"28","author":"V Strand","year":"2010","unstructured":"Strand V, Khanna D (2010) The impact of rheumatoid arthritis and treatment on patients\u2019 lives. Clin Exp Rheumatol 28:S32\u2013S40","journal-title":"Clin Exp Rheumatol"},{"key":"4956_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/annrheumdis-2014-205726","volume":"75","author":"RF van Vollenhoven","year":"2016","unstructured":"van Vollenhoven RF, \u00d8stergaard M, Leirisalo-Repo M, Uhlig T, Jansson M, Larsson E, Brock F, Franck-Larsson K (2016) Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis 75:52\u201358. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205726","journal-title":"Ann Rheum Dis"},{"key":"4956_CR5","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/ard.2009.121491","volume":"69","author":"Y Tanaka","year":"2010","unstructured":"Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, Nojima T, Miyasaka N, Koike T, investigators RRRs (2010) Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 69:1286\u20131291. https:\/\/doi.org\/10.1136\/ard.2009.121491","journal-title":"Ann Rheum Dis"},{"key":"4956_CR6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jbspin.2008.11.009","volume":"76","author":"O Brocq","year":"2009","unstructured":"Brocq O, Millasseau E, Albert C, Grisot C, Flory P, Roux CH, Euller-Ziegler L (2009) Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 76:350\u2013355. https:\/\/doi.org\/10.1016\/j.jbspin.2008.11.009","journal-title":"Joint Bone Spine"},{"key":"4956_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1136\/annrheumdis-2014-205752","volume":"74","author":"TW Huizinga","year":"2015","unstructured":"Huizinga TW, Conaghan PG, Martin-Mola E, Schett G, Amital H, Xavier RM, Troum O, Aassi M, Bernasconi C, Dougados M (2015) Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis 74:35\u201343. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205752","journal-title":"Ann Rheum Dis"},{"key":"4956_CR8","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/art.39626","volume":"68","author":"M Ghiti Moghadam","year":"2016","unstructured":"Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaardenburg D, Starmans-Kool M, Brouwer E, Bos R, Lems WF, Colin EM, Allaart CF, Meek IL, Landewe R, Bernelot Moens HJ, van Riel PL, van de Laar MA, Jansen TL, Dutch National PC (2016) Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: a pragmatic multicenter, open-label randomized controlled trial. Arthritis Rheumatol 68:1810\u20131817. https:\/\/doi.org\/10.1002\/art.39626","journal-title":"Arthritis Rheumatol"},{"key":"4956_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/art.33383","volume":"64","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, Connell CA, Gruben D, Krishnaswami S, Wallenstein G, Wilkinson BE, Zwillich SH (2012) Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 64:617\u2013629. https:\/\/doi.org\/10.1002\/art.33383","journal-title":"Arthritis Rheum"},{"key":"4956_CR10","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/art.33419","volume":"64","author":"JM Kremer","year":"2012","unstructured":"Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik KS, Krishnaswami S, Pascual-Ramos V, Wallenstein G, Zwillich SH (2012) A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 64:970\u2013981. https:\/\/doi.org\/10.1002\/art.33419","journal-title":"Arthritis Rheum"},{"key":"4956_CR11","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1002\/art.24567","volume":"60","author":"JM Kremer","year":"2009","unstructured":"Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, Krishnaswami S, Burgos-Vargas R, Wilkinson B, Zerbini CAF, Zwillich SH (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60:1895\u20131905. https:\/\/doi.org\/10.1002\/art.24567","journal-title":"Arthritis Rheum"},{"key":"4956_CR12","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3109\/14397595.2014.995875","volume":"25","author":"Y Tanaka","year":"2015","unstructured":"Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyoizumi S, Zwillich S (2015) Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol 25:514\u2013521. https:\/\/doi.org\/10.3109\/14397595.2014.995875","journal-title":"Mod Rheumatol"},{"key":"4956_CR13","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/acr.20494","volume":"63","author":"Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH, Tofacitinib Study Investigators","year":"2011","unstructured":"Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH, Tofacitinib Study Investigators (2011) Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 63:1150\u20131158. https:\/\/doi.org\/10.1002\/acr.20494","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4956_CR14","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Soma K, Bradley J, Mebus C, on behalf of the ORAL Step Investigators (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381:451\u2013460. https:\/\/doi.org\/10.1016\/S0140-6736(12)61424-X","journal-title":"Lancet"},{"key":"4956_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS, for the ORAL Solo Investigators (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367:495\u2013507. https:\/\/doi.org\/10.1056\/NEJMoa1109071","journal-title":"N Engl J Med"},{"key":"4956_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer J, Li Z-G, Hall S, Fleischmann R, Genovese M, Martin-Mola E, Isaacs JD, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Riese R, Bradley J (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159:253\u2013261. https:\/\/doi.org\/10.7326\/0003-4819-159-4-201308200-00006","journal-title":"Ann Intern Med"},{"key":"4956_CR17","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley J, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C, Zwillich SH, van Vollenhoven RF, for the ORAL Start Investigators (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370:2377\u20132386. https:\/\/doi.org\/10.1056\/NEJMoa1310476","journal-title":"N Engl J Med"},{"key":"4956_CR18","doi-asserted-by":"publisher","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, Cardiel MH, Cohen S, Nash P, Song YW, Tegzov\u00e1 D, Wyman BT, Gruben D, Benda B, Wallenstein G, Krishnaswami S, Zwillich SH, Bradley JD, Connell CA, and the ORAL Scan Investigators (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65:559\u2013570. https:\/\/doi.org\/10.1002\/art.37816","DOI":"10.1002\/art.37816"},{"key":"4956_CR19","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garc\u00eda Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B, for the ORAL Standard Investigators (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367:508\u2013519. https:\/\/doi.org\/10.1056\/NEJMoa1112072","journal-title":"N Engl J Med"},{"key":"4956_CR20","doi-asserted-by":"publisher","unstructured":"Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS, on behalf of the ORAL Strategy investigators (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 390:457\u2013468. https:\/\/doi.org\/10.1016\/S0140-6736(17)31618-5","DOI":"10.1016\/S0140-6736(17)31618-5"},{"key":"4956_CR21","doi-asserted-by":"publisher","unstructured":"Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, Nduaka CI, Benda B, Gruben D, Nakamura H, Komuro Y, Zwillich SH, Wang L, Riese RJ (2014) Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 41:837-852. https:\/\/doi.org\/10.3899\/jrheum.130683","DOI":"10.3899\/jrheum.130683"},{"key":"4956_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13075-016-0932-2","volume":"18","author":"H Yamanaka","year":"2016","unstructured":"Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S, Morishima Y, Hirose T, Zwillich S (2016) Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther 18:34. https:\/\/doi.org\/10.1186\/s13075-016-0932-2","journal-title":"Arthritis Res Ther"},{"key":"4956_CR23","doi-asserted-by":"publisher","unstructured":"Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K, Soma K, Mojcik C, DeMasi R, Strengholt S, Kwok K, Lazariciu I, Wang L, Cohen S (2019) Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther 21:89. https:\/\/doi.org\/10.1186\/s13075-019-1866-2","DOI":"10.1186\/s13075-019-1866-2"},{"key":"4956_CR24","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, Gomez-Reino J, Soma K, Mebus C, Wilkinson B, Hodge J, Fan H, Wang T, Bingham CO 3rd (2016) The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis 75:687\u2013695. https:\/\/doi.org\/10.1136\/annrheumdis-2014-207191","journal-title":"Ann Rheum Dis"},{"key":"4956_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"AM van Gestel","year":"1996","unstructured":"van Gestel AM, Prevoo ML, van \u2018t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria. Arthritis Rheum 39:34\u201340","journal-title":"Arthritis Rheum"},{"key":"4956_CR26","doi-asserted-by":"publisher","first-page":"e000232","DOI":"10.1136\/rmdopen-2015-000232","volume":"2","author":"R Fleischmann","year":"2016","unstructured":"Fleischmann R, Strand V, Wilkinson B, Kwok K, Bananis E (2016) Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-na\u00efve patients with rheumatoid arthritis. RMD Open 2:e000232. https:\/\/doi.org\/10.1136\/rmdopen-2015-000232","journal-title":"RMD Open"},{"key":"4956_CR27","doi-asserted-by":"publisher","unstructured":"Kaine J, Tesser J, DeMasi R, Takiya L, Wang L, Snyder M, Fan H, Bandi V, Wollenhaupt J (2018) OP0037 Efficacy of tofacitinib after temporary discontinuation in patients with rheumatoid arthritis: analysis of data from open-label long-term extension studies. Ann Rheum Dis 77:69\u201370. https:\/\/doi.org\/10.1136\/annrheumdis-2018-eular.3755","DOI":"10.1136\/annrheumdis-2018-eular.3755"},{"key":"4956_CR28","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jbspin.2018.02.002","volume":"85","author":"B Fautrel","year":"2018","unstructured":"Fautrel B (2018) Therapeutic strategy for rheumatoid arthritis patients who have achieved remission. Joint Bone Spine 85:679\u2013685. https:\/\/doi.org\/10.1016\/j.jbspin.2018.02.002","journal-title":"Joint Bone Spine"},{"key":"4956_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/annrheumdis-2011-200344","volume":"71","author":"J Kaine","year":"2012","unstructured":"Kaine J, Gladstein G, Strusberg I, Robles M, Louw I, Gujrathi S, Pappu R, Delaet I, Pans M, Ludivico C (2012) Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase IIIb ALLOW study). Ann Rheum Dis 71:38\u201344. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200344","journal-title":"Ann Rheum Dis"},{"key":"4956_CR30","unstructured":"US Department of Health and Human Services (2011) Clinical pharmacology and biopharmaceutics review(s). Application Number:203214Orig1s000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203214Orig1s000ClinPharmR.pdf. Accessed 10 Jan 2019"},{"key":"4956_CR31","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","volume":"33","author":"JR Curtis","year":"2011","unstructured":"Curtis JR, Singh JA (2011) Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther 33:679\u2013707. https:\/\/doi.org\/10.1016\/j.clinthera.2011.05.044","journal-title":"Clin Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-04956-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-020-04956-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-04956-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T14:37:49Z","timestamp":1613054269000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-020-04956-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,12]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["4956"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-04956-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,12]]},"assertion":[{"value":"3 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice Guidelines and was approved by the Institutional Review Boards and\/or Independent Ethics Committees at each investigational center.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"J Kaine and J Tesser have received grant\/research support from, are consultants for, and are on the speaker\u2019s bureau for, Pfizer Inc. R DeMasi was an employee and shareholder of Pfizer Inc. at the time of the analysis. L Takiya, L Wang, M Snyder, K Soma, and H Fan are employees and shareholders of Pfizer Inc. V Bandi is a consultant for Pfizer Inc. through the Eliassen Group Inc. J Wollenhaupt is a consultant for, and is on the speaker\u2019s bureau for, Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}